Structural Dynamics of OATP1A2 in Mediating Paclitaxel Transport Mechanism in Breast Cancer

Rohit Kumar1, Garima Singh2, Yusuf Akhter2

  • 1Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University), Vidya Vihar, Raebareli Road, Lucknow- 226025, Uttar Pradesh, India.

Nanotheranostics
|March 13, 2025
PubMed

Insights

This study reveals Solute Carrier Organic Anion Transporter Polypeptide 1A2 (OATP1A2) unexpectedly transports paclitaxel (PTX) outward, challenging assumptions for breast cancer drug delivery. The findings suggest complex OATP1A2 interactions impacting PTX bioavailability.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Computational Biology

Background:

  • Breast cancer treatment faces challenges from drug resistance and poor bioavailability of agents like paclitaxel (PTX).
  • Solute Carrier Organic Anion Transporter Polypeptide 1A2 (OATP1A2) is a potential transporter of various organic anions, including drugs.
  • Understanding OATP1A2's role in PTX transport is crucial for optimizing breast cancer chemotherapy.

Purpose of the Study:

  • To investigate the interaction between OATP1A2 and paclitaxel (PTX) using computational methods.
  • To elucidate the transport mechanism and structural dynamics of OATP1A2 concerning PTX.

Main Methods:

  • Computational modeling of the OATP1A2 structure using Phyre2.
  • Molecular docking to predict PTX binding sites and affinity.
  • 500 ns molecular dynamics (MD) simulations to analyze protein-ligand interactions and dynamics.

Main Results:

  • Molecular docking predicted a binding affinity of -10.4 kcal/mol for PTX within OATP1A2, with specific hydrogen and hydrophobic interactions.
  • Contrary to hypothesis, MD simulations showed PTX unexpectedly moving outwards (5.4 Å) from the binding site.
  • The OATP1A2-PTX complex remained stable during simulations, displaying significant conformational changes.

Conclusions:

  • OATP1A2-mediated PTX transport is more complex than a simple inward uptake mechanism.
  • The outward transport suggests potential limitations for OATP1A2 in enhancing PTX bioavailability for breast cancer.
  • Findings provide insights into transporter-mediated drug delivery, potentially guiding future strategies for improved chemotherapeutic efficacy.

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
227
ABC Transporters: Exporter01:31

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
4.1K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
23
Nonlinear Pharmacokinetics: Role of Transporters01:27

Nonlinear Pharmacokinetics: Role of Transporters

A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
25
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K